Multiple recent complaints describe billing issues, impossible cancellations, and unresponsive customer service
This mode lowers their resting metabolic rate, making it more difficult to maintain weight loss following semaglutide injections
Prefer to speak with someone
In the drugs best showing so far, the ATTAIN-1 trial, people taking orforglipron lost on average 12.4% of their baseline weight, a notch below the roughly 14% weight loss seen in similar trials of Novo Nordisks injectable Wegovy and also below the typical results seen with Eli Lillys tirzepatide, a dual GLP-1/GIP medication
Chan School of Public Health analyzed 3,572 pregnancies in women who were taking GLP-1 drugs prior to conception, including 1,467 in women with type 2 diabetes